S. Rubinraut

发表

Novel extended and branched N-terminal analogs of VIP

I. Gozes, M. Fridkin, D. Dangoor, 2006, Regulatory Peptides.

Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.

Y. Shechter, M. Fridkin, M. Fridkin, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin.

Y. Shechter, M. Fridkin, S. Rubinraut, 2005, Bioconjugate chemistry.

Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.

I. Gozes, D. Brenneman, M. Fridkin, 1998, The Journal of pharmacology and experimental therapeutics.

New Technologies to Prolong Life-time of Peptide and Protein Drugs In vivo

B. Mester, Y. Shechter, M. Fridkin, 2007, International Journal of Peptide Research and Therapeutics.

Preventive Treatment of Alzheimer’s Disease

I. Gozes, A. Bardea, D. Brenneman, 1998 .

Inhibition of human neuroblastoma growth by a specific VIP antagonist

I. Gozes, G. Lilling, D. Brenneman, 2007, Journal of Molecular Neuroscience.

Microwave Discharge of O2 and CO2 as a Synthetic Tool for Oxidations of Unsaturated Compounds Adsorbed on Solid Supports

Y. Mazur, S. Rubinraut, E. Zadok, 1983 .

VIP‐derived sequences modified by N‐terminal stearyl moiety induce cell death: the human keratinocyte as a model

I. Gozes, M. Fridkin, S. Rubinraut, 2000, FEBS letters.

Reactions of phenylethylenes with O(3P) atoms in condensed phases

Y. Mazur, S. Rubinraut, E. Zadok, 1987 .

Metalloid derivatives for oganic synthesis the preparation of urazole and thiourazole derivatives

A. Shanzer, S. Rubinraut, 1979 .

Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.

I. Gozes, A. Bardea, R. Zamostiano, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.

Y. Shechter, M. Fridkin, K. Sasson, 2012, Bioconjugate chemistry.

Novel analogs of VIP with multiple C-terminal domains

I. Gozes, M. Fridkin, D. Dangoor, 2007, Peptides.

P Agonists and 1 Tissue and ity : Effects on ration , Sexual Biologic Clock "

T. Moody, O. Ashur-Fabian, I. Gozes, 2006 .

Intranasal Delivery of Bioactive Peptides or Peptide Analogues Enhances Spatial Memory and Protects Against Cholinergic Deficits

I. Gozes, A. Pinhasov, M. Fridkin, 2001 .

Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.

O. Ashur-Fabian, I. Gozes, M. Fridkin, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Neuropeptides and Neuronal Survival: Neuroprotective Strategy for Alzheimer's Disease a

I. Gozes, A. Bardea, R. Zamostiano, 1997, Annals of the New York Academy of Sciences.

Development of VIP Agonists and Antagonists with Tissue and Receptor Specificity: Effects on Behavioral Maturation, Sexual Function, and the Biologic Clock a

T. Moody, O. Ashur-Fabian, I. Gozes, 1996, Annals of the New York Academy of Sciences.

Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease.

I. Gozes, A. Bardea, M. Fridkin, 1997, Journal of neurobiology.

Reactions of di-, tri-, and hexamethylbenzenes with oxygen(3P) atoms in liquid and on adsorbed phases

F. Frolow, Y. Mazur, S. Rubinraut, 1985 .

Reversible pegylation of insulin facilitates its prolonged action in vivo.

Y. Shechter, M. Fridkin, Y. Marcus, 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

The amyloidogenic domains of the human serum amyloid A protein--new insights.

M. Fridkin, S. Rubinraut, Emanuel Perugia, 2009, Advances in experimental medicine and biology.

Establishing the principle of reversibility in peptide/protein and small-molecule therapy.

Y. Shechter, M. Fridkin, Y. Marcus, 2012, Therapeutic delivery.

Ozonolysis by microwave discharge of oxygen of naphthalene adsorbed on florisil

Y. Mazur, S. Rubinraut, E. Zadok, 1984 .

Protection Against Developmental Deficiencies by a Lipophilic VIP Analogue

I. Gozes, A. Bardea, M. Fridkin, 1998, Neurochemical Research.

Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.

I. Gozes, G. Lilling, I. Ashkenazi, 1995, The Journal of pharmacology and experimental therapeutics.

Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.

I. Gozes, M. Fridkin, S. Rubinraut, 1994, Endocrinology.

Thiolysis of the 3-nitro-2-pyridinesulfenyl (Npys) protecting group. An approach towards a general deprotection scheme in peptide synthesis.

M. Fridkin, S. Rubinraut, O. Rosen, 1990, International journal of peptide and protein research.

Protection against developmental and learning impairments in apolipoprotein e-deficient mice by activity-dependent femtomolar-acting peptides

I. Gozes, A. Bardea, D. Brenneman, 1997, Neuroscience Letters.

The Design, Synthesis, and Biological Evaluation of VIP and VIP Analogs

I. Gozes, M. Fridkin, D. Dangoor, 2008 .

Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.

I. Gozes, D. Brenneman, M. Fridkin, 1998, The Journal of pharmacology and experimental therapeutics.

Multiple Actions of a Hybrid PACAP Antagonist: Neuronal Cell Killing and Inhibition of Sperm Motility a

I. Gozes, R. Zamostiano, M. Fridkin, 1998, Annals of the New York Academy of Sciences.